Key regions: France, Europe, United Kingdom, Brazil, India
The demand for Oncology Drugs in Northern Europe is experiencing a steady growth due to several factors.
Customer preferences: Northern European countries are known for their well-established healthcare systems and high healthcare spending per capita. The aging population and increasing incidence of cancer are driving the demand for oncology drugs in the region. Patients in Northern Europe prefer targeted therapies and immunotherapies due to their higher efficacy and lower toxicity compared to traditional chemotherapy.
Trends in the market: The oncology drugs market in Northern Europe is witnessing a shift towards personalized medicine. The use of biomarkers and genetic testing is increasing, allowing for more targeted treatments. The market is also seeing an increase in the development and adoption of biosimilars, which are cheaper alternatives to biologic drugs. The increasing focus on precision medicine and the development of new therapies is expected to drive the market growth in the region.
Local special circumstances: Northern Europe is known for its strict regulatory environment and high pricing of drugs. The pricing and reimbursement policies in the region are determined by national health technology assessment (HTA) agencies. The HTA agencies evaluate the clinical and economic value of drugs before deciding on their pricing and reimbursement. This has led to a slower uptake of new drugs in the region, but also ensures that only drugs with proven efficacy and value are available to patients.
Underlying macroeconomic factors: The economies of Northern European countries are stable, with high GDP per capita and low unemployment rates. The healthcare systems in the region are publicly funded, which ensures that patients have access to healthcare services and drugs regardless of their income. The region also has a strong focus on research and development, which has led to the development of several innovative drugs for cancer treatment. The increasing incidence of cancer and the aging population are also driving the demand for oncology drugs in the region.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
